| Literature DB >> 22891248 |
Heiko Kroth1, Annalisa Ansaloni, Yvan Varisco, Asad Jan, Nampally Sreenivasachary, Nasrollah Rezaei-Ghaleh, Valérie Giriens, Sophie Lohmann, María Pilar López-Deber, Oskar Adolfsson, Maria Pihlgren, Paolo Paganetti, Wolfgang Froestl, Luitgard Nagel-Steger, Dieter Willbold, Thomas Schrader, Markus Zweckstetter, Andrea Pfeifer, Hilal A Lashuel, Andreas Muhs.
Abstract
Increasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in the pathogenesis of Alzheimer disease. Thus, inhibiting Aβ aggregation, among others, has emerged as a potential therapeutic intervention for this disorder. Herein, we employed 3-aminopyrazole as a key fragment in our design of non-dye compounds capable of interacting with Aβ42 via a donor-acceptor-donor hydrogen bond pattern complementary to that of the β-sheet conformation of Aβ42. The initial design of the compounds was based on connecting two 3-aminopyrazole moieties via a linker to identify suitable scaffold molecules. Additional aryl substitutions on the two 3-aminopyrazole moieties were also explored to enhance π-π stacking/hydrophobic interactions with amino acids of Aβ42. The efficacy of these compounds on inhibiting Aβ fibril formation and toxicity in vitro was assessed using a combination of biophysical techniques and viability assays. Using structure activity relationship data from the in vitro assays, we identified compounds capable of preventing pathological self-assembly of Aβ42 leading to decreased cell toxicity.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22891248 PMCID: PMC3464581 DOI: 10.1074/jbc.M112.357665
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157